论文部分内容阅读
目的实验将对前列地尔联合胰激肽原酶治疗早期糖尿病足的治疗效果进行实际探究。方法该次实验选取了2016年6—12月在该院就诊的70例糖尿病足患者,随机分为对照组和观察组,对照组采用常规治疗方式,包括对血糖、血压的控制,改善患者微循环;观察组则在此基础上使用前列地尔联合胰激肽原酶进行治疗,随后对比治疗有效性。结果观察组治疗有效率为91.43%,明显优于对照组的74.28%,且在临床症状和创口愈合方面有较好的恢复效果,两组差异有统计学意义(P<0.05)。结论使用前列地尔联合胰激肽原酶对早期糖尿病足的治疗具有显著成效,有利于改善患者的微循环,患者满意度高,值得在临床治疗中推广应用。
The purpose of the experiment will be prostaglandin combined pancreatic kallikrein treatment of early diabetic foot to explore the actual effect. Methods In this experiment, 70 patients with diabetic foot treated in our hospital from June to December in 2016 were randomly divided into control group and observation group. The control group was treated with conventional therapy, including the control of blood glucose and blood pressure, The observation group was then treated with alprostadil plus pancreatic kallidinogenase and the efficacy of the treatment was compared. Results The effective rate of observation group was 91.43%, which was significantly better than that of control group (74.28%), and had good recovery in clinical symptoms and wound healing. The difference between the two groups was statistically significant (P <0.05). Conclusions The use of alprostadil combined with pancreatic kallidinogenase has a significant effect on the treatment of early diabetic foot, which is beneficial to improve the microcirculation of patients. The patient satisfaction is high and worthy of promotion and application in clinical treatment.